Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Open accessPublished version of a preprint
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n = 978) and on-treatment (n = 171) ctDNA samples across 16 advanced-stage tumor types from three phase I/II trials of durvalumab (± the anti-CTLA4 therapy tremelimumab). Higher pretreatment variant allele frequencies (VAF) were associated with poorer overall survival (OS) and other known prognostic factors, but not objective response, suggesting a prognostic role for patient outcomes. On-treatment reductions in VAF and lower on-treatment VAF were independently associated with longer progression-free survival and OS and increased objective response rate, but not prognostic variables, suggesting that on-treatment ctDNA dynamics are predictive of benefit from immune checkpoint blockade. Accordingly, we propose a concept of “molecular response” using ctDNA, incorporating both pretreatment and on-treatment VAF, that predicted long-term survival similarly to initial radiologic response while also permitting early differentiation of responders among patients with initially radiologically stable disease. Significance: In a pan-cancer analysis of immune checkpoint blockade, pretreatment ctDNA levels appeared prognostic and on-treatment dynamics predictive. A “molecular response” metric identified long-term responders and adjudicated benefit among patients with initially radiologically stable disease. Changes in ctDNA may be more dynamic than radiographic changes and could complement existing trial endpoints. This article is highlighted in the In This Issue feature, p. 1775
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, integration of longitudinal blood-based assays such as circulating-tumor DNA (ctDNA; ref. 216), which are easier to implement and less invasive as opposed to longitudinal tumor biopsies, is under investigation as a method to monitor responses to ICT.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [216]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Self-citationAtezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Cited by
Items 201–300 of 376
Clinical Utility of ctDNA Analysis in Lung Cancer—A Review
Makar, K., Wróbel, A., Antczak, A. J., & Tworek, D. (2025) · Advances in respiratory medicine · doi:10.3390/arm93030017 · Cited by 10
Qian, K., & Liu, Q. (2023) · Translational Breast Cancer Research · doi:10.21037/tbcr-23-17 · Cited by 10
Huang, Q., Mitsiades, I. R., Dowst, H., Zarrin‐Khameh, N., Noor, A. B., Castro, P. D., Scheurer, M. E., Godoy, G., Mims, M. P., & Mitsiades, N. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00467-9 · Cited by 10
Computational Modeling for Circulating Cell-Free DNA in Clinical Oncology
Phuong, L. N., Salas, S., & Benzekry, S. (2025) · JCO Clinical Cancer Informatics · doi:10.1200/cci-24-00224 · Cited by 10
Carbonell, C., Frigola, J., Pardo, N., Callejo, A., Iranzo, P., Valdivia, A., Priano, I., Cedrés, S., Martínez‐Martí, A., Navarro, A., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13409 · Cited by 10
Tatalovic, S., Doleschal, B., Kupferthaler, A., Grundner, S., Burghofer, J., Webersinke, G., Schwendinger, S., Jukic, E., Zschocke, J., Danhel, L., et al. (2024) · Cancers · doi:10.3390/cancers16233960 · Cited by 10
Efficacy assessment in phase I clinical trials: endpoints and challenges
Gouda, M. A., Ballesteros, P. Á., Garrido‐Laguna, I., & Rodon, J. A. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.02.010 · Cited by 10
Late phase 1 studies: concepts and outcomes
Benítez, J. C., Géraud, A., Texier, M., Massard, C., Paci, A., Soria, J., & Besse, B. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00467-8 · Cited by 10
Circulating tumor DNA: Opportunities and challenges for pharmacometric approaches
Ribba, B., Roller, A., Helms, H., Stern, M., & Bleul, C. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1058220 · Cited by 10
Yang, F., Tang, M., Cui, L., Bai, J., Yu, J., Gao, J., Nie, X., Xu, L., Xia, X., Yi, X., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15098 · Cited by 10
Ma, Q., Hou, S., Ma, H., Gao, J., & Song, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1574449 · Cited by 10
Drill, E. N., Qiu, A. Q., Shapouri, S., To, T. M., RAVELO, A. G., Schade, J., Dawson, K. L., & Matasar, M. J. (2021) · ONCOLOGY · doi:10.46883/2021.25920935 · Cited by 9
Huang, S., Liang, Y., Liu, N., & Ma, J. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1151-5 · Cited by 9
Broccard, S. P., Kasbi, A. A., Bagaria, S. P., Jones, J. C., Shoukry, M. M., & Gabriel, E. M. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-470 · Cited by 9
Honoré, N., Laliotis, G., Aushev, V. N., Velichko, S., Palsuledesai, C. C., Dahou, H., van Marcke, C., Galot, R., Liu, M., & Machiels, J. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1309 · Cited by 9
Ciardullo, C., Tobalina, L., Carr, T. H., Szekeres, P. G., Kraljevic, S., Byers, L. A., & Fabbri, G. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2011 · Cited by 9
Zhou, F., Zhang, J., Ren, S., Chen, J., Li, F., Ma, T., Fang, Y., Wang, Q., Yao, W., Guo, R., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.05.021 · Cited by 9
Wei, J., Wang, Y., Gao, J., Li, Z., Pang, R., Zhai, T., Ma, Y., Wang, Z., & Meng, X. (2022) · Microchemical Journal · doi:10.1016/j.microc.2022.107452 · Cited by 9
Translating noninvasive molecular responses into clinical reality for cancer immunotherapy
Murray, J. C., & Anagnostou, V. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00450-4 · Cited by 9
Markovets, A. A., Vega, D. M., Abbosh, C., Quinn, K., Chang, K., Wienke, S., Hartmaier, R. J., Barrett, J. C., & Hodgson, D. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00287 · Cited by 9
Self-citationCherifi, F., Ray-Coquard, I. L., Rubio, M. J., Paolettí, X., Lorusso, D., Choi, C. H., Hasegawa, K., Tan, D. S. P., Hudson, E., Davis, A. J., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2496133 · Cited by 9
A macrophage-T cell coculture model for severe tissue injury-induced T cell death
Zhu, J., Cao, J., Liesz, A., & Roth, S. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.100983 · Cited by 9
Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma
Jani, Y. C., Jansen, C. S., Gerke, M. B., & Bilen, M. A. (2024) · Immunotherapy · doi:10.2217/imt-2023-0267 · Cited by 8
Perspectives for circulating tumor DNA in clinical management of colorectal cancer
Takemasa, I., Hamabe, A., & Ishii, M. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01937-5 · Cited by 8
Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms
Cowzer, D., Shah, R. H., Chou, J. F., Kundra, R., Punn, S., Fiedler, L. M., DeMore, A., Capanu, M., Berger, M. F., Reidy‐Lagunes, D. L., et al. (2024) · Endocrine Related Cancer · doi:10.1530/erc-23-0292 · Cited by 8
Martelli, V., Vidal, J., Gibert, J., Fernández‐Rodríguez, C., Linares, J., Alfonso, P. G., Páez, D., Alonso, V., Gómez‐España, A., Guix, M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105760 · Cited by 9
Lyu, D., Liu, B., Lan, B., Sun, X., Li, L., Zhai, J., Qian, H., & Ma, F. (2022) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2022.04.03 · Cited by 8
Park, C., Jun, H. R., Oh, H., Lee, J., Cho, H.-J., Kim, Y., Lee, J. E., Yoon, S. H., Choi, C., Lee, J. C., et al. (2023) · Cells · doi:10.3390/cells12091246 · Cited by 8
Hua, W., Liu, J., Li, Y., Yin, H., Shen, H., Wu, J., Kong, Y., Pan, B., Liang, J., Wang, L., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70150 · Cited by 8
Self-citationMack, P. C., Redman, M. W., Tukachinsky, H., Kozono, D., Minichiello, K., Dragnev, K. H., Tolba, K. A., Neal, J. W., Madison, R. W., Waqar, S. N., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3658 · Cited by 7
Brasó‐Maristany, F., Sansó, M., Chic, N., Martínez, D., González‐Farré, B., Sanfeliu, E., Ghiglione, L., Carcelero, E., García-Corbacho, J., Sánchez, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.710596 · Cited by 7
Pontolillo, L., Davis, A. A., Gerratana, L., Medford, A. J., Wang, J. J., Nicolò, E., Clifton, K., Velimirovic, M., Warrior, S., Podany, E. L., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00802-2 · Cited by 7
Lam, R. C. T., Johnson, D., Lam, G., Li, M. L. Y., Wong, J. W. L., Lam, W. K., Chan, K. C. A., & Ma, B. B. Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.970242 · Cited by 7
Gelmini, S., Calabri, A., Mancini, I., Comin, C., Pasini, V., Banini, M., Scotti, V., & Pinzani, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020611 · Cited by 7
Zhou, S., Shen, C., Wang, Y., Zhao, Z., & Che, G. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-265 · Cited by 7
Tuerhong, N., Yang, Y., Feng, J., He, B., Huang, P., Wen, F., & Li, Q. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000004588 · Cited by 7
Long, C., Li, K., Liu, Z., Zhang, N., Xing, X., Xu, L., Gai, F., & Che, N. (2023) · Cancer Medicine · doi:10.1002/cam4.5582 · Cited by 7
Inagaki, C., Kawakami, H., Maeda, D., Sakai, D., Urakawa, S., Nishida, K., Kudo, T., Doki, Y., Eguchi, H., Wada, H., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-32645-x · Cited by 7
Lieb, V., Abdulrahman, A., Weigelt, K., Hauch, S., Gombert, M., Guzman, J., Bellut, L., Goebell, P. J., Stöhr, R., Hartmann, A., et al. (2021) · Cells · doi:10.3390/cells10113223 · Cited by 7
Role of Nanomedicine in Transforming Pharmacotherapy for Substance Use Disorder ( SUD )
Patne, A. Y., Mohapatra, S., & Mohapatra, S. S. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70008 · Cited by 6
Standish, L. J., Malani, S. S., Lynch, K., Whinkin, E., McCotter, C. M., Lynch, D. A., & Aggarwal, S. K. (2023) · Integrative Cancer Therapies · doi:10.1177/15347354231178911 · Cited by 6
Dincman, T. A., Karam, J. A. Q., Giordano, A., Li, H., Drusbosky, L. M., Gourdin, T. S., Howe, P. H., & Lilly, M. B. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1202277 · Cited by 6
Liu, S. M., Sun, H., Zhou, J., Zhang, J., Yin, K., Chen, Z., Su, J., Zhang, X., Yang, J., Zhou, Q. H., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101254 · Cited by 6
Liquid biopsy for guiding breast cancer immunotherapy
Fina, E., Vitale, E., Summa, S. D., Gadaleta‐Caldarola, G., Tommasi, S., Massafra, R., Brunetti, O., & Rizzo, A. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2479426 · Cited by 6
Shi, M., Yuan, H., Ji, J., Zhang, S., Li, Q., Chen, Y., Gong, X., Zhu, Z., & Zhang, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211070643 · Cited by 6
Gensheimer, M. F., Kotha, N. V., Vitzthum, L. K., Chin, A. L.-C., Jackson, S., Erve, I. V. ’., Pratapneni, A., Le-Budka, M.-L., Wong, S., Brown, E., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.09.038 · Cited by 6
Chen, C., Huang, L., Chen, Z., Ou, Q., Liu, S., Jiang, X., Chen, F., Wei, X., Guo, H., Shao, Y. W., et al. (2023) · Advanced Biology · doi:10.1002/adbi.202300042 · Cited by 6
Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma
Chung, C., Galvin, R. M., Achenbach, E., Dziadkowiec, O., & Sen, S. (2021) · ONCOLOGY · doi:10.46883/2021.25920931 · Cited by 6
Ramelyte, E., Kött, J., Lawless, A. R., Ciernik, A., Heidrich, I., Zellweger, C., Montazeri, K., Mangana, J., Smit, D. J., Freiberger, S. N., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2274 · Cited by 6
Cas13-mediated liquid biopsy: A comprehensive review of cancer diagnostic applications
Gao, M., Wu, S., Hu, X., Zhu, L., Hu, Y., He, X., He, J., Rong, Y., Zhang, Y., Liu, C., et al. (2025) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2025.118411 · Cited by 6
Self-citationCrnovrsanin, N., Zeeuw, M. J., Ali, M., Kemna, R., Alipanahi, B., Lumbard, K., Skidmore, Z. L., Rinaldi, L., Erve, I. V. ’., Wesdorp, N. J., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.106081 · Cited by 6
Neoadjuvant toripalimab combined with chemotherapy in locally advanced HNSCC
Wang, Z., Yang, S., Yan, D., Zhang, Y., Zhang, X., Zhang, F., Zhao, X., Zhang, Z., Liu, S., Gui, L., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1571776 · Cited by 6
Circulating biomarkers of response to immunotherapy and immune-related adverse events
Garrison, Z. R., Hornick, N. I., Cheng, J. B., & Kulkarni, R. P. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2130688 · Cited by 5
Mao, L., Yang, M., Fan, X., Li, W., Huang, X., He, W., Lin, T., & Huang, J. (2023) · Cancer Innovation · doi:10.1002/cai2.75 · Cited by 5
Towards liquid biopsy-based analysis of antitumour immunity
Pantel, K., Masmoudi, D., & Alix‐Panabières, C. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01181-8 · Cited by 5
Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)
Gouda, M. A., Jankú, F., Yuan, Y., Drusbosky, L. M., Chen, A. P., Zheng, X., Patel, K. P., Hamilton, S. R., Routbort, M. J., Tricoli, J. V., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3531 · Cited by 5
Guardamagna, M., Zamorano, E., Albarrán-Artahona, V., Mesas, A., & Benítez, J. C. (2025) · Cancers · doi:10.3390/cancers17132244 · Cited by 5
Gambardella, V., McKean, M. A., Kim, R., Kato, S., Cassier, P. A., Mehnert, J. M., Chmielowski, B., Gaudy‐Marqueste, C., Chen, C. T., Planchard, D., et al. (2026) · JCO oncology advances. · doi:10.1200/oa-25-00114 · Cited by 5
Grandes avances en el diagnóstico y tratamiento del cáncer colorrectal (CRC)
Jiménez, P., Canro, F., Bonilla, C., Ávila, V., & García‐Foncillas, J. (2024) · Medicina · doi:10.56050/01205498.2377 · Cited by 5
Rahadiani, N., Stephanie, M., Manatar, A. F., & Krisnuhoni, E. (2024) · Oncology Research and Treatment · doi:10.1159/000543030 · Cited by 5
Circulating-tumour DNA (ctDNA) in NSCLC: mechanisms, evidence and the future of MRD detection
Jiménez-Munárriz, B., Urtecho, S. B., Rabey, M. R., & Leighl, N. B. (2026) · BMJ Oncology · doi:10.1136/bmjonc-2025-001002 · Cited by 4
Shimada, Y., Nakano, M., Matsumoto, A., Ozeki, H., Abe, K., Tajima, Y., Yamai, D., Nogami, H., Nakano, M., Tani, T., et al. (2025) · Cancers · doi:10.3390/cancers17132233 · Cited by 4
Circulating Tumor DNA and [18F]FDG-PET for Early Response Assessment in Patients with Advanced NSCLC
Ryssel, H., Ahlborn, L. B., Dejanović, D., Keller, S. H., Poehl, M., Østrup, O., Loft, A., Fischer, B. M., Langer, S. W., Kjær, A., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15030247 · Cited by 4
Lim, J. U., Oya, Y., Fu, R., Sooi, K. W. X., Ang, Y., & Soo, R. A. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2630026 · Cited by 4
He, Z., Duval, V., Jauslin, P. M., Gonçalves, A., Abegesah, A., Fan, C., Lim, K., Song, X., Chen, C. C.-K., Shi, X., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3063 · Cited by 4
Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma
Sterner, J., Rizk, K., Braudis, K., Tuncer, T., & Smith, E. H. (2021) · ONCOLOGY · doi:10.46883/2021.25920933 · Cited by 4
Hu, Y., Narayan, A., Xu, Y., Wolfe, J., Vu, D., Trinh, T., Kantak, C., Ivy, S. P., Eder, J. P., Deng, Y., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00289 · Cited by 4
Tanaka, K., Sugimura, K., Matsuura, N., Shiraishi, O., Momose, K., Yamashita, K., Sugase, T., Kanemura, T., Makino, T., Takeno, A., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-18042-w · Cited by 4
Matsubara, N., Kusuhara, S., Yamamoto, N., Sudo, K., Yanagita, M., Murayama, K., Kawasumi, H., Russell, D. L., Yin, D., & Shimizu, T. (2023) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04605-9 · Cited by 4
Zhu, Z., Bao, X., Shi, H.-Y., & Gu, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1283008 · Cited by 3
Andersen, M. E., Nyhus, C. H., Szejniuk, W. M., Wahlstrøm, S., Timm, S., Pallisgaard, N., Madsen, M. G., Mikkelsen, M. D., Ahlborn, L. B., Gehl, J., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-100311 · Cited by 3
Sanz‐García, E., Soleimani, S., Bruce, J. P., Pedersen, S., Tang, M., Avery, L. M., Eagles, J., Spreafico, A., Hansen, A. R., Eng, L., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3541 · Cited by 3
Lieb, V., Abdulrahman, A., Weigelt, K., Hauch, S., Gombert, M., Guzman, J., Bellut, L., Goebell, P. J., Stöhr, R., Hartmann, A., et al. (2022) · Cells · doi:10.3390/cells11223618 · Cited by 3
Mansour, R., Shreba, A., Khaddour, K., Georgeos, M., & Alshehabi, Z. (2025) · Cancer Reports · doi:10.1002/cnr2.70234 · Cited by 3
Liquid biopsies, are we ready for prime time?
Normanno, N., Apostolidis, K., & Stewart, M. D. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006302 · Cited by 3
Circulating Tumor DNA in Genitourinary Malignancies: Current Applications and Future PerspectivesPreprint
Chaux, A. (2025) · Preprints.org · doi:10.20944/preprints202506.0995.v1 · Cited by 3
Silvestro, A., Baden, J. F., Billings, K., Bramlett, K. S., Corner, A. S., Danek, T., Deras, I. L., Dickey, J. O., Godsey, J. H., Guan, L., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01243 · Cited by 3
Zhang, X., Shan, H., Pan, H., Zhong, Q., Fang, Q., Xu, Y. Y., Liu, Y., & Qu, S. (2025) · The International Journal of Biological Markers · doi:10.1177/03936155251315500 · Cited by 3
Batra, U., Sharma, M., Nathany, S., Sachdeva, R., Batra, V., Venkataraman, P., Dewan, A., Choudhary, S. K., & Mehta, A. (2025) · Lung India · doi:10.4103/lungindia.lungindia_127_25 · Cited by 3
Rischin, D., Hansen, A. R., Cohen, E. E. W., Tahara, M., Harrington, K. J., Haddad, R. I., Licitra, L. F., Mehanna, H. M., Ferris, R. L., Koralewski, P., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1197 · Cited by 3
Gan, N., Liu, P., Zeng, T., Chen, S., Mo, Y., Zhong, J., Song, Y., Chen, Y., & Wu, D. (2026) · ACS Sensors · doi:10.1021/acssensors.6c01378 · Cited by 3
Ye, D., Zhao, Y., Yang, L., Sun, X., Cao, T., Yuan, M., Qiao, T., Xing, L., & Sun, X. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102545 · Cited by 2
Immune checkpoint inhibitors in dMMR-MSI-H colorectal cancer: rationale, progress and prospects
Xu, G., Liang, D., Li, L. S., Cheng, J., & Wang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1828717 · Cited by 2
Schenk, D., Davis, M. J., Zhou, R., Mantilla, A., Galbraith, M., Spiro, O., Petrillo, O., do Valle, Í. F., Ferguson, A. R., Jooss, K. U., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.04.626817 · Cited by 2
[Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in Non-small Cell Lung Cancer].
Wang, P., Tang, C., & Liang, J. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.102.24 · Cited by 2
Kakouri, A. C., Spiliotaki, M., Loizidou, E. M., Stylianou, I., Papageorgiou, E., Panayi, C., Constantinou, A. I., Charalambous, H., Deltas, C. C., & Papagregoriou, G. (2025) · Translational Lung Cancer Research · doi:10.21037/tlcr-2024-1095 · Cited by 2
Teixeira, M. F., Fahmy, N., & Kasi, P. M. (2026) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.12.010 · Cited by 2
Longitudinal methylated ctDNA increases predict immunotherapy progression across solid tumors
Anees, M., Wagner, P. L., Omstead, A. N., Grayhack, E. E., Sherry, C., McDaniel, L., Varga, M. G., Hosseiny, S. M. H., LaFramboise, W., Nakayama, J., et al. (2026) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2026.100477 · Cited by 2
Ito, M., Kubo, M., Kawaji, H., Otsubo, Y., Kurata, K., Abutani, H., Suyama, M., Oda, Y., Yoshizumi, T., Nakamura, M., et al. (2023) · Cancers · doi:10.3390/cancers15235608 · Cited by 2
[Research Progress of Circulating Tumor DNA in Non-small Cell Lung Cancer].
Lei, S., & Wang, Y. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.35 · Cited by 2
The clinical utility of circulating tumor DNA in colorectal cancer: A narrative review
Lakshmi, V., Rakesh, M., Narmadha, M. P., Sudhindran, S., Balakrishnan, D., & Koyakutty, M. (2024) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_225_23 · Cited by 2
Overdijk, M. B., Strumane, K., Plummer, R., LoRusso, P. M., Rodon, J. A., Banerji, U., Garralda, E., Calvo, E., Si, H., Hoevenaars, N., et al. (2026) · Clinical and Translational Science · doi:10.1111/cts.70546 · Cited by 2
Self-citationQing, D., Lu, Z., & Lu, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1585844 · Cited by 2
Circulating Tumor DNA in Urothelial Cancer: Practical Applications in Oncology Clinic
Mittal, K., Mouw, K. W., & Singh, P. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00734 · Cited by 2
Moretto, R., Studiale, V., Hyun, S. W., Vetere, G., Islam, F., Carullo, M., Conca, V., Lo, C., Neems, D. S., Boulos, H., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4641 · Cited by 2
From concept to clinic: emerging paradigms and novel insights into liquid biopsy
Guo, W., Liu, Y., Dong, H., Li, X., Guo, X. Y., Guo, H., Zhou, K., & Xing, J. (2026) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2025.0830 · Cited by 2
Riudavets, M., Birsen, G., Slomka, J., Alitano, M., Damotte, D., & Wislez, M. (2025) · Bulletin du Cancer · doi:10.1016/s0007-4551(25)00156-0 · Cited by 1
Profiling KRAS mutations in whole blood by error-corrected maximum depth sequencing
Ramaker, R. C., Zhang, Y., Strickler, J. H., Allen, P., Abbruzzese, J. L., & Counter, C. M. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01399-w · Cited by 1
Development and Validation of a 7-eRNA Prognostic Signature for Lung Adenocarcinoma
Sun, Y., Chen, K., Zhang, J., Hu, Z., Xiong, M., Fang, Z., Chen, G., Meng, X., Liao, B., Xiong, Y., et al. (2025) · Biology · doi:10.3390/biology14101431 · Cited by 1
Shaya, S., Uche–Ikonne, O., Kilerci, B., Stevenson, J., Greystoke, A., Cook, N., Thistlethwaite, F. C., Carter, L., Graham, D. M., & Krebs, M. (2025) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-25-11 · Cited by 1
Metadata
- Authors
- Zhang, Q., Luo, J., Wu, S., Si, H., Gao, C., Xu, W., Abdullah, S. E., Higgs, B. W., Dennis, P. A., van der Heijden, M. S., Segal, N. H., Chaft, J. E., Hembrough, T., Barrett, J. C., & Hellmann, M. D.
- Affiliations
- 1Translational Medicine, Early Oncology, AstraZeneca, Gaithersburg, Maryland.
- Memorial Sloan Kettering Cancer Center (US)
- 3Early Oncology Statistics, AstraZeneca, Gaithersburg, Maryland.
- AstraZeneca (United States) (US)
- 5Division of Molecular Carcinogenesis and Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, the Netherlands.
- Corresponding author
- Hellmann, Matthew D.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-12-01
- Volume
- 10
- Issue
- 12
- Pages
- 1842-1853
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC8358981
- OpenAlex
- W3049083268
- Cited by
- 348
- References
- 53
- Citations by year
- 2026: 31 · 2025: 72 · 2024: 60 · 2023: 70 · 2022: 54 · 2021: 54 · 2020: 6
- FWCI
- 16.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- AstraZeneca (NCT01693562, NCT02087423, NCT02261220)
- Memorial Sloan Kettering Cancer Center (P30 CA008748)
- Damon Runyon Cancer Research Foundation (CI-98-18)
- Parker Institute for Cancer Immunotherapy
- NIH (T32-CA009207, K30-UL1TR00457)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- circulating tumor DNA, immune checkpoint blockade, durvalumab, tremelimumab, variant allele frequency, molecular response, prognostic factors, predictive biomarkers, overall survival, progression-free survival, objective response rate, pan-cancer analysis, CTLA-4 blockade
- MeSH terms
- Circulating Tumor DNA, Immune Checkpoint Inhibitors, Humans, Neoplasms, Prognosis, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.